Skin cancer: Targeted therapy for melanoma: is double hitting a home run?
15:55 EST 4 Dec 2012 | Nature Publishing
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK inhibitors with BRAF inhibition alone showed increased progression-free survival and reduced incidence of secondary malignancies in patients with mutant BRAF V600 melan..
Original Article: Skin cancer: Targeted therapy for melanoma: is double hitting a home run?
More From BioPortfolio on "Skin cancer: Targeted therapy for melanoma: is double hitting a home run?"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
